tiprankstipranks
Jazz Pharmaceuticals (JAZZ)
NASDAQ:JAZZ

Jazz Pharmaceuticals (JAZZ) Stock Forecast & Price Target

1,200 Followers
See the Price Targets and Ratings of:

JAZZ Analyst Ratings

Strong Buy
12Ratings
10 Buy
2 Hold
0 Sell
Based on 12 analysts giving stock ratings to
Jazz
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

JAZZ Stock 12 Months Forecast

Average Price Target

$185.91
▲(40.54% Upside)
Based on 12 Wall Street analysts offering 12 month price targets for Jazz Pharmaceuticals in the last 3 months. The average price target is $185.91 with a high forecast of $235.00 and a low forecast of $135.00. The average price target represents a 40.54% change from the last price of $132.28.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"plus_tr_sans","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"118":"$118","177":"$177","236":"$236","147.5":"$147.5","206.5":"$206.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":235,"label":{"className":"overflowvisible_force","align":"right","x":60,"y":-17.5,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">$235.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":185.91,"label":{"className":"overflowvisible_force","align":"right","x":60,"y":-7.5,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">$185.91</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":135,"label":{"className":"overflowvisible_force","align":"right","x":60,"y":2.5,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">$135.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[118,147.5,177,206.5,236],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2023","6":"Aug<br/>2023","9":"Nov<br/>2023","12":"Feb<br/>2024","25":"Feb<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,122.9,131.52307692307693,140.14615384615385,148.76923076923077,157.3923076923077,166.01538461538462,174.63846153846154,183.26153846153846,191.8846153846154,200.5076923076923,209.13076923076923,217.75384615384615,226.37692307692308,{"y":235,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,122.9,127.74692307692308,132.59384615384616,137.44076923076923,142.2876923076923,147.1346153846154,151.98153846153846,156.82846153846154,161.67538461538462,166.5223076923077,171.36923076923077,176.21615384615384,181.06307692307692,{"y":185.91,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,122.9,123.83076923076923,124.76153846153846,125.6923076923077,126.62307692307692,127.55384615384615,128.48461538461538,129.41538461538462,130.34615384615384,131.27692307692308,132.2076923076923,133.13846153846154,134.06923076923078,{"y":135,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":147.73,"date":1676592000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":146.12,"date":1677801600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":147.16,"date":1680825600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":139.4,"date":1683244800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":128.34,"date":1685664000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":122,"date":1688688000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":130.14,"date":1691107200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":143.76,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":128.92,"date":1696550400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":132.06,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":119.11,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":127.6,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":122.9,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$235.00Average Price Target$185.91Lowest Price Target$135.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Needham
$225.00
Buy
70.09%
Upside
Reiterated
11/28/23
Buy Rating on Jazz Pharmaceuticals: Long-Term Growth Despite JZP441 Setback
UBS
$135.00
Hold
2.06%
Upside
Downgraded
11/27/23
UBS downgrades Jazz Pharmaceuticals (JAZZ) to NeutralUBS analyst Ashwani Verma downgraded Jazz Pharmaceuticals (NASDAQ: JAZZ) from Buy to Neutral with a price target of $135.00 (from $170.00).
Truist Financial
$200.00
Buy
51.19%
Upside
Reiterated
11/09/23
Analysts Offer Insights on Healthcare Companies: Veracyte (NASDAQ: VCYT), Jazz Pharmaceuticals (NASDAQ: JAZZ) and Tenaya Therapeutics (NASDAQ: TNYA)
TD Cowen
$225.00
Buy
70.09%
Upside
Reiterated
11/08/23
Jazz Pharmaceuticals: A Promising Buy with Sustained Growth and Undervalued Shares
Raymond James
Hold
Initiated
09/28/23
Jazz Pharmaceuticals initiated with a Market Perform at Raymond JamesJazz Pharmaceuticals initiated with a Market Perform at Raymond James

Best Analysts Covering Jazz Pharmaceuticals

Which Analyst Should I Follow If I Want to Buy JAZZ and Sell After:
1 Month
Ami FadiaNeedham
Success Rate
20/28 ratings generated profit
71%
Average Return
+1.81%
reiterated a buy rating 3 months ago
Copying Ami Fadia's trades and holding each position for 1 Month would result in 71.43% of your transactions generating a profit, with an average return of +1.81% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
3 Months
Ami FadiaNeedham
Success Rate
18/28 ratings generated profit
64%
Average Return
+3.26%
reiterated a buy rating 3 months ago
Copying Ami Fadia's trades and holding each position for 3 Months would result in 64.29% of your transactions generating a profit, with an average return of +3.26% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
1 Year
Annabel SamimyStifel Nicolaus
Success Rate
11/18 ratings generated profit
61%
Average Return
+5.19%
assigned a buy rating 2 months ago
Copying Annabel Samimy's trades and holding each position for 1 Year would result in 61.11% of your transactions generating a profit, with an average return of +5.19% per trade.
2 Years
Jason GerberryBank of America Securities
Success Rate
19/34 ratings generated profit
56%
Average Return
+6.27%
reiterated a buy rating 2 months ago
Copying Jason Gerberry's trades and holding each position for 2 Years would result in 55.88% of your transactions generating a profit, with an average return of +6.27% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

JAZZ Analyst Recommendation Trends

Rating
Oct 23
Nov 23
Dec 23
Jan 24
Feb 24
Strong Buy
7
11
12
10
4
Buy
4
1
2
5
4
Hold
2
2
2
2
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
13
14
16
17
9
In the current month, JAZZ has received 8 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. JAZZ average Analyst price target in the past 3 months is $185.91.
Each month's total comprises the sum of three months' worth of ratings.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

JAZZ Financial Forecast

JAZZ Earnings Forecast

Next quarter’s earnings estimate for JAZZ is $5.18 with a range of $4.75 to $5.62. The previous quarter’s EPS was $4.84. JAZZ beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.57% of the time in the same period. In the last calendar year JAZZ has Underperformed its overall industry.
Next quarter’s earnings estimate for JAZZ is $5.18 with a range of $4.75 to $5.62. The previous quarter’s EPS was $4.84. JAZZ beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.57% of the time in the same period. In the last calendar year JAZZ has Underperformed its overall industry.

JAZZ Sales Forecast

Next quarter’s sales forecast for JAZZ is $1.01B with a range of $960.00M to $1.04B. The previous quarter’s sales results were $972.14M. JAZZ beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 47.09% of the time in the same period. In the last calendar year JAZZ has Outperformed its overall industry.
Next quarter’s sales forecast for JAZZ is $1.01B with a range of $960.00M to $1.04B. The previous quarter’s sales results were $972.14M. JAZZ beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 47.09% of the time in the same period. In the last calendar year JAZZ has Outperformed its overall industry.

JAZZ Stock Forecast FAQ

What is JAZZ’s average 12-month price target, according to analysts?
Based on analyst ratings, Jazz Pharmaceuticals’s 12-month average price target is $185.91.
    What is JAZZ’s upside potential, based on the analysts’ average price target?
    Jazz Pharmaceuticals has 40.54% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is JAZZ a Buy, Sell or Hold?
          Jazz Pharmaceuticals has a conensus rating of Strong Buy which is based on 10 buy ratings, 2 hold ratings and 0 sell ratings.
            What is Jazz Pharmaceuticals’s price target?
            The average price target for Jazz Pharmaceuticals is $185.91. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $235.00 ,the lowest forecast is $135.00. The average price target represents 40.54% Increase from the current price of $132.28.
              What do analysts say about Jazz Pharmaceuticals?
              Jazz Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.
                How can I buy shares of JAZZ?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis